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Abstract: Prostate cancer (PCa) is a leading cause of mortality and morbidity globally. While genomic
alterations have been identified in PCa, in contrast to some other cancers, use of such information to
personalize treatment is still in its infancy. Here, we discuss how PAGE4, a protein which appears
to act both as an oncogenic factor as well as a metastasis suppressor, is a novel therapeutic target
for PCa. Inhibiting PAGE4 may be a viable strategy for low-risk PCa where it is highly upregulated.
Conversely, PAGE4 expression is downregulated in metastatic PCa and, therefore, reinstituting its
sustained expression may be a promising option to subvert or attenuate androgen-resistant PCa.
Thus, fine-tuning the levels of PAGE4 may represent a novel approach for personalized medicine
in PCa.
Keywords: PAGE4; prostate cancer; symptomatic BPH; Cancer/Testis Antigen; ADT; IAD
1. Introduction
According to a relatively recent report, ‘An Aging World: 2015’ commissioned by the National
Institute of Aging of the United States and produced by the US Census Bureau, the world’s elderly
population continues to grow at an unprecedented rate. Almost 8.5% of the world’s population
(617 million) is aged 65 and over, and this number is projected to mushroom to nearly 17% (1.6 billion)
by 2050. Given that the incidence of both prostate cancer (PCa) and benign prostatic hyperplasia (BPH)
increase with age, it is obvious that these diseases affect a large fraction of the elderly male population,
and underscore the urgent need for effective therapies and strategies to treat and manage them.
Here, we first briefly review the current treatment options for the two diseases and present
evidence which indicates that PAGE4, a remarkably prostate-specific protein, can be a novel,
multifaceted pharmacological target for these desperate maladies. Next, we examine the unique
structural features of the PAGE4 protein ensemble (or more specifically, the lack of a specific structure).
We discuss how the aberrant expression of PAGE4 and its conformational dynamics may enable this
protein to contribute to the progression of BPH from an asymptomatic to a severe symptomatic form.
Finally, we review data indicating PAGE4 may function both as an oncogenic factor in early-stage PCa
J. Clin. Med. 2018, 7, 156; doi:10.3390/jcm7060156 www.mdpi.com/journal/jcm
J. Clin. Med. 2018, 7, 156 2 of 14
and as a metastasis suppressor in advanced disease, and argue how its conformational malleability
could be exploited as its Achilles heel.
1.1. Prostate Cancer
PCa is a major global healthcare issue. In 2018, it is estimated that we will see ~165,000 new
diagnoses and >29,000 deaths from the disease in the US alone [1]. Indeed, according to the American
Cancer Society, it is the third leading cause of cancer-related death in men. Since the advent of the
prostate-specific antigen (PSA) assay and improved detection of biopsy samples, metastatic disease at
presentation has become a rarity in the urology clinic. However, in 2012 the United States Preventive
Services Task Force recommended that healthy men should no longer be screened for PCa because the
test does not save lives overall, and often leads to more tests and over-diagnosis. However, proponents
continue to argue in favour of PSA-based screening and the debate continues [2–5].
Nonetheless, a continuing problem in urology today is the large number of patients with either
abnormally high PSA/negative biopsies or patients with positive biopsies but low Gleason scores
(≤6 with no Gleason 4) [6–8]. Many of the patients in this category who are over 60 years of age will
undergo active treatment that is unlikely to extend their life span [9,10]. With no medical modalities to
treat or prevent the disease in the early stages, this unsettled group is usually considered as low or
very low risk for PCa by the clinicians. Patients in this group are, thus, advised to follow the active
surveillance (AS) protocol [11,12]. This protocol involves close monitoring of PSA levels combined
with periodic imaging and repeat biopsies with the intention of avoiding treatment unless there is
evidence of disease progression [11,13,14].
Despite this cautious approach, however, the disease progresses in a significant fraction of these
patients [15], and much to the chagrin of the urologists, they face an imminent danger of developing a
high-risk disease. Indeed, it is estimated that as many as 40% [11] and up to 58% [16] of the patients
under AS progress to “high-risk” (GS ≥7) PCa that can become metastatic and potentially turn lethal.
In the recent ProtecT (Prostate Testing for Cancer and Treatment) trial [17], 1643 men were randomly
assigned to radical prostatectomy, external beam radiation, or AS. The trial found that ~10% of patients
in the AS group had developed metastatic disease or died of PCa at 10 years, thus underscoring the
lurking danger for these patients.
Unfortunately, until recently, reliable biomarkers that can distinguish between high-risk PCa
patients who are likely to progress to metastatic disease, from low-risk patients whose disease is
unlikely to progress were not available to urologists. This lack of precision may have contributed
to significant “overtreatment” of patients who would have otherwise required only conservative
management [18]. However, the advent of advanced technologies and sophisticated bioinformatics
algorithms has fueled the discovery of novel biomarkers that can be helpful for post-biopsy
decision-making in low-risk patients and post-radical prostatectomy in selected risk groups [19].
Although intended to be used in combination with the accepted clinical criteria to stratify PCa
according to biological aggressiveness and direct initial patient management, these new biomarkers
are gaining acceptance. Despite the rising popularity, additional studies are still needed to investigate
the clinical benefit of these new technologies, the financial ramifications and their utilization in the
clinic. Notwithstanding these challenges, there are still no therapeutic options that can be offered to
patients with low-risk PCa.
On the other hand, the treatment course for patients with high-risk disease is definitive
and is given with the intent to cure the cancer. Patients are typically recommended surgery
followed by androgen deprivation therapy (ADT). However, many patients with non-metastatic
yet androgen-resistant PCa (CRPC), an earlier stage of PCa, can experience disease progression despite
ADT. Unfortunately, no Federal Drug Administration (FDA) approved treatment options are presently
available for this condition until these patients develop metastatic disease. Notwithstanding the
potential side effects of surgery [20] and the failure of ADT due to the emergence of CRPC in most
patients pursuant to an initial positive response [21,22], the big question is how do we address androgen
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resistance in the future? Developing the so-called “next-gen” drugs to an old target (i.e., androgen
receptor (AR)), even if they are more effective [23–25], are not likely to be a viable long-term solution,
because there are no guarantees that the disease will not evolve resistance against them. Then, how can
the transition from low-risk to high-risk disease be thwarted? And how can CRPC be treated without
the ensuing drug resistance?
1.2. Benign Prostatic Hyperplasia
BPH is the most common pathologic and clinical abnormality associated with the prostate gland.
Indeed, histologic BPH lesions are encountered in men as young as in their 20s and 30s and the
prevalence of the disease continues to rise as they age [26]. Although accurate estimates like those
available for PCa are not available for BPH, epidemiological data indicate that asymptomatic BPH
affects 50% of all men by the time they turn 50, and escalates to >90% in men 85 years or older [27,28].
While BPH is often histologic, a significant fraction of men have symptomatic forms of the disease
which can result in lower urinary tract symptoms and even bladder outlet obstruction. It thus follows
that BPH and PCa can coexist in the same patient.
1.3. Coincidence of BPH and Prostate Cancer
Although PCa typically presents in men in their late 60s [29], the disease has been detected in
men who are only in their 20s [30]. In fact, the coexistence of BPH and PCa has been known for
>60 years. In an autopsy study of cadavers with and without PCa, Sommers [31] found that BPH was
present in 80% of cadavers with PCa and only in 45% of cadavers without PCa. It therefore seems quite
probable that most men diagnosed with PCa also have histologic BPH. Consistently, Ørsted et al. [32],
who evaluated over 3 million Danish men, found that BPH was associated with an increased incidence
of PCa as well as resulting mortality from the disease. However, the authors cautioned that their data
underscoring the coincidence of the two diseases should not be used to infer causality between the two.
On the other hand, Kulkarni and Getzenberg [33] have argued that there could be a causal relationship
between the two diseases.
Regardless, however, it is quite imminent that most men diagnosed with BPH, and in particular
symptomatic BPH, will have PCa within their prostate glands. In addition to the practically ubiquitous
histologic association, both diseases share many commonalities in their etiologies including androgen
dependence, smoking, a diet high in fat [34], and inflammation [35–38]. Finally, epidemiological
studies are weighted towards the presence of BPH increasing the risk for a man to develop PCa in
his lifetime [39,40]. Considered together, it seems reasonable to hypothesize that, at a mechanistic
level, one or more common factor(s) may underlie the etiology of symptomatic BPH and PCa and if so,
targeting such factor(s) would satisfy the unmet medical needs of these diseases that account for a
significant portion of the healthcare burden worldwide, particularly in the industrialized world.
1.4. PAGE4, a Factor Common to Both BPH and PCa
In this section, we discuss how Prostate-Associated Gene 4 (PAGE4) may not only be the missing
link between symptomatic BPH and PCa, but also a highly validated target for these burgeoning
urologic diseases.
First, PAGE4 is a Cancer/Testis Antigen (CTA). The CTAs are a heterogeneous group of proteins
that are by definition typically restricted to the testis, an immune-privileged organ, but are aberrantly
expressed in cancer [41–43]. Furthermore, while PAGE4 is remarkably prostate-specific in men,
its expression is highly dynamic. PAGE4 protein is highly upregulated both spatially and temporally
in the prostatic epithelium and stromal cells of the fetal prostate up to 21 weeks, but is undetectable
by 36 weeks [44]. In contrast, PAGE4 is undetectable in the normal adult prostate [45]. However,
PAGE4 protein is highly expressed in the epithelial cells in Proliferative Inflammatory Atrophy (PIA)
lesions and in high-grade Prostatic Intraepithelial Neoplasia (PIN) lesions [45], both of which are
thought to be PCa precursors [46]. Furthermore, while PAGE4 protein expression is upregulated in
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primary (organ-confined, androgen-dependent) PCa, metastatic PCa specimens show no detectable
PAGE4 protein [45,47,48] (Figure 1), which is in excellent agreement with the mRNA expression pattern
(Table 1) [47]. These data suggest that PAGE4 may actually function as a proto-oncoprotein that is
important in early development but is pathological if aberrantly expressed in the adult prostate gland.
Consistent with this hypothesis, PAGE4 mRNA is significantly upregulated when somatic cells are
reprogrammed to form induced pluripotent stem (iPS) cells but is undetectable in the parent somatic
cells used in reprogramming [49]. Moreover, while knocking down PAGE4 expression results in cell
death in vitro, its overexpression results in a growth advantage of PCa cells [50].
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Table 1. PAGE4 expression is down regulated in metastatic prostate cancer; CTA, Cancer/Testis 
Antigen (CTA). 
CTA BPH Primary PCa Met PCa 
PAGE4 (205564_at) 6732.5 5702.8 56.6 
CSAG2 (220445_s_at) 16.6 20.6 1026.4 
MAGEA2 (214603_at) 46.7 42.7 1343.9 
MAGEA6 (214612_x_at) 30.5 16.2 2785.1 
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Second, PAGE4 protein is highly overexpressed in symptomatic BPH, which shares similarities 
with PCa at the molecular level, but not in asymptomatic BPH (also referred to as histologic or 
Figure 1. Immunohistochemistry analysis of Prostate-associated Gene 4 (PAGE4) in prostate cancer.
(A) Negative staining in the normal prostate. (B) Intense staining shown in the stromal tissue in benign
prostatic hyperplasia (BPH). (C) Positive staining in the stromal cells but negative in the cancer cells
in some prostate cancer (PCa) specimens. (D) Moderate staining in the cancer cells but negative in
the stromal cells in some PCa specimens. (E) Positive staining in the atrophic glands but negative in
the cancer cells (arrowhead). (F) Negative staining in metastatic PCa. (G) Intense staining shown in
cancer adjacent “normal” glands (asterisk) associated with inflammation but only moderate staining
in the cancer cells (arrowhead). (H) High power view of boxed area in (G). Asterisk, proliferative
inflammatory atrophy (PIA) lesions; arrows, inflammatory cells. Scale bars in all panels, 100 µm.
Table 1. PAGE4 expression is down regulated in metastatic prostate cancer; CTA, Cancer/Testis
Antigen (CTA).
CTA BPH Primary PCa Met PCa
PAGE4 (205564_at) 6732.5 5702.8 56.6
CSAG2 (220445_s_at) 16.6 20.6 1026.4
MAGEA2 (214603_at) 46.7 42.7 1343.9
MAGEA6 (214612_x_at) 30.5 16.2 2785.1
MAGEA12 (210467_x_at) 34.9 52.9 1168.4
TBP (203135_at) 608.66 577.58 882.2
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Second, PAGE4 protein is highly overexpressed in symptomatic BPH, which shares similarities
with PCa at the molecular level, but not in asymptomatic BPH (also referred to as histologic or
incidental BPH) [51]. In addition, unlike in the case of PCa where PAGE4 expression is observed in
epithelial cells, in BPH, PAGE4 protein is predominantly expressed in the stromal and smooth muscle
cells [51]. Considered together, the extensive spatiotemporal and cell-type specific expression data in
the fetal and diseased gland suggest that PAGE4 appears to play important roles in both benign and
malignant disease of the prostate, perhaps by modulating the effects of inflammatory stress.
Third, consistent with its role as a stress-response protein, PAGE4 is upregulated in response to a
variety of stress inducers including inflammatory stress. Thus, exposing PCa cells to any environmental
(drug treatment) or nutrient stress (glucose deprivation), or treating them with the proinflammatory
cytokine tumor necrosis factor alpha (TNF-α), results in upregulation of PAGE4 both at the mRNA
and protein levels [45]. Perhaps the most tantalizing evidence supporting PAGE4 as a molecular
link between stress and PCa onset comes from the observation that PAGE4 is upregulated in normal
prostate epithelial cells when exposed to the above-mentioned stress inducers [45]. The fact that
PAGE4 is upregulated in PCa precursor lesions affected by inflammatory stress lends further credence
to this argument. Indeed, inflammation appears to play an important role in both BPH, especially
symptomatic BPH, and PCa [51–53]. In fact, as noted earlier, current epidemiological data indicate that
>25% of all cancers are related to chronic infections and other types of unresolved inflammation and
chronic inflammation is now regarded as an “enabling characteristic” of all human cancers including
PCa [36–38].
Fourth, PAGE4 is phosphorylated at S9 and T51 by Homeodomain-Interacting Protein Kinase
1 (HIPK1), a component of the cellular stress–response pathway, and this doubly phosphorylated
PAGE4 (HIPK1-PAGE4) functions as a strong potentiator of the oncoprotein c-Jun [54]. c-Jun is also
a component of the stress–response pathway, and forms a heterodimer with members of the Fos
family to produce Activator Protein-1 (AP-1). This group of early response transcription factors
represents a paradigm for signal-responsive factors with important roles in the control of cell growth,
apoptosis, and stress response [55]. The AP-1 factors are also upregulated in PCa [56] as well as
in symptomatic but not asymptomatic BPH [52], underscoring the mechanistic significance of the
PAGE4/AP-1 interactions in these diseases. Phosphorylation at T51 is necessary for the activity of
HIPK1-PAGE4, because a mutation in this residue to an alanine abolishes its activity by >90% [54].
In addition to HIPK1, PAGE4 is also phosphorylated by CDC-Like Kinase 2 (CLK2), a dual-specificity
kinase that phosphorylates serine-rich (SR) proteins of the spliceosome complex. But in contrast
to HIPK1, CLK2 hyperphosphorylates PAGE4 at multiple S/T residues (including S9 and T51).
Hyperphosphorylation by CLK2 attenuates rather than potentiates c-Jun transactivation [57]. Thus,
in response to differential phosphorylation by the two kinases, PAGE4 could be remodeled to populate
distinct conformational ensembles that may play an important role in regulating the phenotype
of PCa cells in terms of their dependence on androgen (see below). Interestingly, while PAGE4,
HIPK1, and CLK2 are all up-regulated in PCa, they are differentially expressed in PCa cells. Thus,
CLK2, like PAGE4, is expressed in androgen-dependent PCa while HIPK1 is expressed both in
androgen-dependent and androgen-independent PCa cells [57].
Fifth, like the majority of the CTAs, especially the CT-X subgroup [58], PAGE4 is a highly
intrinsically disordered protein (IDP) [50]. Thus, the protein is characterized by lack of a rigid 3D
structure and exists as an ensemble of interconverting conformations instead (hence, the ‘dancing
protein cloud’ metaphor, a term coined by Vladimir Uversky [59]), which, if overexpressed, can lead to a
pathological state [60]. However, detailed biophysical investigations revealed that the polypeptide has
some local and long-range conformational preferences that are perturbed by phosphorylation, resulting
in population shifts and altered intramolecular conformational dynamics [61]. Thus, the population of
transient turn-like structures increases upon phosphorylation in a ~20-residue acidic region centered
on T51. This central region becomes more compact and more negatively charged upon phosphorylation
with increasing intramolecular contacts to basic sequence motifs near the N and C termini. Furthermore,
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although flexibility is decreased in the central region of the phosphorylated ensemble, the polypeptide
chain remains disordered and highly dynamic overall. PAGE4 uses a transient helical structure adjacent
to the central acidic region to bind c-Jun in vitro [61].
2. Targeting PAGE4 in Symptomatic BPH and Early-Stage ‘Low Risk’ PCa
2.1. Small Molecule Inhibitors (Disrupt PAGE4/AP-1 Interaction)
From the foregoing, it follows that detailed structure-function studies on PAGE4 and its interaction
with AP-1 may yield additional insights that can potentially be used to identify small molecule
compounds which disrupt the PAGE4/AP-1 complex. In silico studies using molecular dynamic
simulations and computer-assisted drug design could further buttress such attempts and help screen
for small molecule inhibitors. Similar reports in the literature have successfully identified small
molecules against other IDPs that play important roles in chronic diseases [62], lending further credence
to this strategy. The discovery of inhibitors of the onco-protein c-Myc [63,64]; the cell cycle regulator
p27 [65]; and against nuclear protein 1 (NUPRI) [66], a stress protein involved in pancreatic cancer,
are some recent examples of such endeavors. Thus, the availability of small molecule compounds or
drugs could help treat and manage not only symptomatic BPH but also low-risk PCa patients, perhaps
as a pre-emptive preventative measure. One potential issue comes to mind with regard to inhibiting
PAGE4: Could low risk PCa progress to more aggressive forms in the absence of PAGE4? However,
the fact that knocking down PAGE4 leads to cell death due to apoptosis is reassuring [50].
2.2. Immunotherapy
The efficacy of Sipuleucel-T (Provenge), an autologous cellular immunotherapy and the first
immunotherapy product approved by the US FDA, has set a precedent for PCa immunotherapy [67–69].
This treatment approach is emerging as a promising method for chemotherapy-resistant PCa,
and perhaps even early-stage disease. Indeed, accumulating evidence suggests that several CTAs
including PAGE4 may also be good candidates for PCa immunotherapy [70]. In support of this
possibility, Yokokawa et al. [71] reported the identification and characterization of a novel PAGE4
cytotoxic T lymphocyte (CTL) epitope, and the generation of an enhancer agonist of this epitope.
T-cell lines generated from PCa patients using the agonist peptide showed high levels of lysis of
PAGE4-expressing tumor cells and enhanced secretion of Interferon gamma (IFN-g), granzyme B,
Tumor Necrosis factor alpha (TNF-a), Interleukin 2 (IL-2) and lymphotactin. Thus, these studies provide
the rationale for the potential utility of the novel PAGE4 agonist epitope. As illustrated in Figure 2,
one possible immunotherapeutic approach to treating PCa is to utilize PAGE4 immunogenic peptides.
Per this paradigm, immunogenic peptides corresponding to the PAGE4 molecule are generated;
they are used to pulse in vitro immature dendritic cells isolated from the patient. The pulsed cells
mature into professional antigen-presenting cells, which are then injected back into the patient to
trigger an immune response.
As is well known, therapeutic vaccination for cancer treatment depends on T-cell response
to tumor antigen [72]. Therefore, the identification and characterization of immunogenic PAGE4
peptides, together with the identification of respective Human Leukocyte Antigen (HLA) class I
antigen restriction, and the fact that PAGE4 expression is predominantly restricted to the diseased
prostate, makes this approach a highly attractive one for PCa immunotherapy. However, several
issues will still need to be addressed. For example, low expression levels of PAGE4 coupled with the
notorious tumor heterogeneity can make this treatment option challenging. Second, heterogeneity in
PAGE4 expression could also impair immunogenicity and immune recognition of cancer cells by the
immune system, resulting in decreased vaccination efficacy. Finally, it is conceivable that tumour cell
heterogeneity could lead to the emergence of PAGE-negative neoplastic clones, capable of escaping
treatment-induced and PAGE4-specific immune surveillance.
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Figure 2. Schematic diagram of an immunotherapeutic approach to treating urological malignancies
that utilizes immunogenic peptides corresponding to CTAs. A tumour sample is profiled for CTA
expression using DNA microarrays. A CTA ‘fingerprint’ is generated and immunogenic peptides
corresponding to the CTAs are generated that are used to pulse in vitro immature dendritic cells
isolated from the patient. The pulsed cells mature into professional antigen-presenting cells, which are
then injected back into the patient to trigger an immune response. Abbreviations: CTA, cancer/testis
antigen; Cy3, cyanine 3; Cy5, cyanine 5. (From Kulkarni et al., 2012 [70]).
3. Reinstituting Sustained PAGE4 Expression in Advanced PCa
As mentioned above, HIPK1-phosphorylated PAGE4 (HIPK1-PAGE4) binds to AP-1 and
potentiates c-Jun, but CLK2-phosphorylated PAGE4 (CLK2-PAGE4) has reduced affinity to AP-1
and attenuates c-Jun. These opposing activities are governed by the conformational dynamics of the
PAGE4 ensemble. CLK2-PAGE4 adopts a more expanded and open conformation as compared to
HIPK1-PAGE4 and nonphosphorylated PAGE4 (WT-PAGE4), as determined by multiple experimental
techniques [57].
Interestingly, CLK2 levels can be lowered by AR activity, which in turn is repressed by c-Jun
transactivation. Therefore, enhanced HIPK1-PAGE4 can indirectly increase CLK2 levels and promote
its hyperphosphorylation to CLK2-PAGE4. These interconnections can, thus, form a negative feedback
loop, which may give rise to oscillations in intracellular levels of the different conformational
ensembles of PAGE4 as well as AR activity, as predicted by a mathematical model [57] (Figure 3). It is
important to note that the population of a given PAGE4 conformational ensemble is dependent on its
phosphorylation status. In other words, cell-to-cell variability due to differential phosphorylation of
PAGE4 can promote phenotypic heterogeneity. Consequently, androgen-dependence of a given cell can
be a time-varying function, i.e., a cell can exhibit various extents of androgen-dependence at different
time points. Moreover, cells in a population need not oscillate synchronously, generating non-genetic
heterogeneity in an otherwise clonal population—an insuperable clinical challenge [73]. These
oscillations can be dampened by ADT or even Intermittent ADT (IAD) [74]. However, the oscillations
can be reinstituted if ADT is abrogated (or if IAD is used instead) suggesting that PCa cells can
potentially transition from an androgen-resistant to and androgen-sensitive phenotype reversibly.
It should be noted that these oscillations are pertinent only for cells that do not undergo cell death in
response to ADT/IAD. This argument is further strengthened by a recent report [75] demonstrating
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that differential phosphorylation of the heat shock factor 1 (Hsf1) generates cell-to-cell variation,
and that this variation rather than the absolute Hsf1 activity promotes phenotypic plasticity in yeast.
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Figure 3. Cell-to cell heterogen ity and dynamic vari t ons in Androgen Receptor (AR) activity in a
isogenic po ulation. (A) Regulatory circuit formed by interactions among Prostate-as ociated Gene
4 (PAGE4), Ho eodo ain-Interacti ( IPK1), CDC-like Kinase 2 (CLK2), c-Jun,
and AR act vity—a negative feedback loop. (B) To panel, in absence of any therapeutic intervention,
this negative f edback loop can le t i t ll l r oscillations in AR activity. Differ nt col red curves
show oscillatory dynamics for two cells in a given isogenic po ulation; these oscillations eed not be
synchronized, thus, generating cell-to-cell het rogeneity. Bottom panel, upon application of Androgen
Deprivation Therapy (ADT) (or eriods of AR inhibition during Intermittent Androgen Deprivati n
Thera y (IAD)), these oscillations can get quenched.
Results from a recent preclinical study employing patient-derived xenografts (PDX) in mice [76]
reinforce the above-mentioned observations of reversible cellular plasticity. This study showed that
when tumor specimens taken from clinically castration-resistant patients were implanted into intact
mice, these resected tumors resulted in androgen-sensitive PDXs that could be maintained by serial
passage in intact male mice. pon castration, these tumors initially responded but subsequently
grew as castration resistant (CR) lines that could be serially maintained in castrated male mice
indicating that cells could transition between androgen-sensitive and androgen-resistant phenotypes
reversibly, and that these transitions may be influenced by microenvironmental conditions such
as the availability of androgen. Furthermore, tumors may contain different clones with varying
androgen sensitivity and thus, varying fitness to different environmental conditions, suggesting that
besides reversible phenotypic switching, additional mechanisms may drive androgen resistance
such as, the outgrowth or dominance of one ‘clonal’ phenotype over the other [77]. While the
oscillations in the PAGE4/AP1-1/AR circuit and their quenching in response to therapy re ains
to be experimentally validated, the potential implications of conformational dynamics of PAGE4 in
giving rise to subpopulations with varying sensitivities to these therapies are quite imminent. Of note,
a recent report by Gallaher et al. [78] who investigated drug resistance in PCa, provides credence to
this argument. By using drug dose modulation or treatment vacations, the authors observed that
adaptive therapy strategies can control the emergence of drug resistance by spatially suppressing
less-fit-resistant populations in favor of treatment-sensitive ones.
4. Conclusions and Outlook
In this perspective, we have shed new light on a prostate-specific protein that has remained
relatively under-appreciated espite he enormous promise it holds as biomarker, as therapeutic
target, and as potential therapeutic itself. As far s we are aware, ther is no other molecule that fits
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these criteria in any cancer, much less in PCa. We have summarized results indicating that inhibiting
PAGE4 using small molecule inhibitors may be a novel therapeutic strategy for symptomatic BPH,
and for low-risk, androgen-sensitive PCa, where it is highly upregulated. We also indicated that
reinstituting PAGE4’s sustained expression in metastatic PCa, where it is downregulated, is likely to
subvert or attenuate the emergence of CRPC. Toward this end, multiple avenues such as oncolytic
viruses [79,80] or nanoparticles [81,82] to deliver protein therapeutic payloads may be contemplated.
Alternatively, IAD may present an unprecedented opportunity to tackle high-risk PCa (Figure 4).
While the jury is still out, and a clear advantage of IAD over ADT remains equivocal, proponents
argue that IAD can abrogate some of the undesirable side effects and costs associated with continuous
ADT while improving the quality of life for PCa patients [3].
J. Clin. Med. 2018, 7, x FOR PEER REVIEW  9 of 14 
 
subvert or a tenuate the emergence of CRPC. Toward this end, multiple avenues such as oncolytic 
viruses [79,80] or nanoparticles [81,82] to deliver protein therapeutic payloads ay e t l t . 
Alternatively, IAD may present an unprecedented opportunity to tackle hig -ris  a ( i r  4). 
While the jury is still out, and a clear advantage of IAD over ADT remains equivocal, proponents 
argue that IAD can abrogate some of the undesirable side e fects and costs associated ith continuous 
ADT while improving the quality of life for PCa patients [3]. 
 
(A) (B) 
Figure 4. Schematic diagram indicating a new type of precision medicine for prostate diseases. (A) In 
symptomatic BPH and in organ-confined prostate cancer where PAGE4 is upregulated, inhibiting 
PAGE4 using small molecule inhibitors may be a novel therapeutic strategy to treat these diseases. (B) 
Reinstituting PAGE4’s sustained expression either by intermittent ADT (IAD) or protein expression 
in metastatic prostate cancer, where it is downregulated, is likely to subvert or attenuate the 
emergence of CRPC. OC, organ-confined; Met, metastatic; AD, androgen-dependent; AI, androgen-
independent. 
In further support of reinstituting PAGE4 expression in advanced disease, two lines of 
tantalizing evidence are noteworthy. First, in a preclinical study, compared to vector only control 
tumors, the growth of PCa xenograft tumors overexpressing PAGE4 was attenuated when the host 
was castrated [83]. These data tend to suggest that the presence of PAGE4 attenuated PCa growth in 
an androgen-depleted background that may, at least conceptually, mimic CRPC. Second, clinical 
studies have revealed that higher levels of PAGE4 are an indicator of better PCa prognosis. Thus, in 
hormone-naive PCa, the median survival of patients with high PAGE4 expression was 8.2 years 
compared with 3.1 years for patients with PAGE4 negative or with low PAGE4 expression [83]. 
Conversely, loss of PAGE4 correlated with poor overall survival in hormone-naive PCa patients. 
Consistently, a lower level of PAGE4 mRNA correlated with reduced incidence of biochemically 
recurrent PCa, although it was not an independent predictor of biochemical recurrence [48] (Figure 
5).  
Furthermore, a serum-based enzyme-linked immunosorbent assay using a monoclonal antibody 
that can detect PAGE4 at a low ng/mL level can distinguish patients with symptomatic and 
asymptomatic BPH with high sensitivity and specificity [84]. Although the presence of PCa in these 
men did not appear to alter PAGE4 levels, this study together with some others [85], highlights the 
potential of biomarker-based screening and gene-specific therapies as tools to risk stratify patients 
with BPH and identify those with symptomatic or medically resistant forms. In summary, though 
additional studies will be needed to fully adjudicate the full potential of PAGE4, it is tempting to 
conjecture that, in the future, PAGE4 could serve as a theranostic marker so that appropriate 
treatment modality (inhibition versus sustained expression) for each patient could be tailored based 
on serum PAGE4 levels heralding a new type of precision medicine for prostate diseases. Thus, 
PAGE4, a hitherto unappreciated molecule, may be the dark horse in the race for an effective therapy 
for these increasingly prevalent prostatic maladies. 
Figure 4. Schematic diagram indicating a new type of precision medicine for prostate diseases. (A) In
symptomatic BPH and in organ-confined prostate cancer where PAGE4 is upregulated, inhibiting
PAGE4 using small molecule inhibitors may be a novel therapeutic strategy to treat these diseases.
(B) Reinstituting PAGE4’s sustained expression either by intermittent ADT (IAD) or protein expression
in metastatic prostate cancer, where it is downregulated, is likely to subvert or attenuate the emergence
of CRPC. OC, organ-confined; Met, metastatic; AD, androgen-dependent; AI, androgen-independent.
In further support of reinstituting PAGE4 expression in advanced disease, two lines of tantalizing
evidence are noteworthy. First, in a preclinical study, compared to vector only control tumors,
the growth of PCa xenograft tumors overexpressing PAGE4 was attenuated when the host was
castrated [83]. These data tend to suggest that the presence of PAGE4 attenuated PCa growth in
an androgen-depleted background that may, at least conceptually, mimic CRPC. Second, clinical
studies have revealed that higher levels of PAGE4 are an indicator of better PCa prognosis. Thus,
in hormone-naive PCa, the median survival of patients with high PAGE4 expression was 8.2 years
compared with 3.1 years for patients with PAGE4 negative or with low PAGE4 expression [83].
Conversely, loss of PAGE4 correlated with poor overall survival in hormone-naive PCa patients.
Consistently, a lower level of PAGE4 mRNA correlated with reduced incidence of biochemically
recurrent PCa, although it was not an independent predictor of biochemical recurrence [48] (Figure 5).
Furthermore, a serum-based enzyme-linked immunosorbent assay using a monoclonal antibody
that can detect PAGE4 at a low ng/mL level can distinguish patients with symptomatic and
asymptomatic BPH with high sensitivity and specificity [84]. Although the presence of PCa in these
men did not appear to alter PAGE4 levels, this study together with some others [85], highlights the
potential of biomarker-based screening and gene-specific therapies as tools to risk stratify patients
with BPH and identify those with symptomatic or medically resistant forms. In summary, though
additional studies will be needed to fully adjudicate the full potential of PAGE4, it is tempting to
conjecture that, in the future, PAGE4 could serve as a theranostic marker so that appropriate treatment
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modality (inhibition versus sustained expression) for each patient could be tailored based on serum
PAGE4 levels heralding a new type of precision medicine for prostate diseases. Thus, PAGE4, a hitherto
unappreciated molecule, may be the dark horse in the race for an effective therapy for these increasingly
prevalent prostatic maladies.
Fig. 5
d
Figure 5. Kaplan–Meier analyses. Kaplan–Meier curves showing biochemical recurrence-free survival
against time after radical prostatectomy stratified by the mRNA expression of (a) CEP55, (b) NUF2
and (c) PAGE4 (high versus low groups dichotomized by median value). (From Shiraishi et al., 2012).
(d) PAGE4 levels correlate with survival of patients with hormone-naive PCa. Overall survival of
patients with hormone-naive PCa after TURP for local advanced obstructive PCa stratified for high
versus negative/low (neg/low) epithelial PAGE4 levels on the advanced PCa TMA (third quartile of
mean epithelial PAGE4 intensity was set as the cut-off level) (From Sampson et al., 2012).
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